Loading
A phase 2 trial of Niraparib, Cetrelimab, Abiraterone acetate and Prednisone in prostate cancer, run by Janssen Research & Development, LLC, active and no longer recruiting.
A Study of Niraparib Combination Therapies for the Treatment of Metastatic Castration-Resistant Prostate Cancer is a phase 2 interventional study registered as NCT03431350 by Janssen Research & Development, LLC, with 136 participants enrolled, started 2018-03-02 and due to reach its primary completion in 2021-08-31. Interventions recorded: Niraparib 200 mg, Cetrelimab 240 mg, Cetrelimab 480 mg, Abiraterone acetate 1000 mg and Prednisone 5 mg. Results have been posted on the registry.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
136 enrolled.
95% CI 9.9 to 43.7; Figures from the ClinicalTrials.gov results section (first posted 2023-11-18), not from a publication · 95% CI 0.5 to 36.4
Source| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Combination 1: Part 2: Objective Response Rate (ORR)primary | Combination 1: Part 2 (Dose Expansion): Cohort 1A: BM+: Niraparib 200 mg + Cetrelimab 480 mg | 21 | 23.8% | - | - | link |
| Combination 1: Part 2 (Dose Expansion): Cohort 1B: BM-: Niraparib 200 mg + Cetrelimab 480 mg | 11 | 9.1% |
Shares Niraparib, Abiraterone acetate, Prednisone, Johnson & Johnson and the tag pipeline.
Shares Abiraterone acetate, Prednisone, Johnson & Johnson, Prostate cancer and the tag pipeline.
Shares Abiraterone acetate, Prednisone, Johnson & Johnson, Metastatic castration-resistant prostate cancer and the tag pipeline.
Shares Cetrelimab, Johnson & Johnson and the tag pipeline.
Shares Prednisone, Johnson & Johnson, Metastatic castration-resistant prostate cancer, Prostate cancer and the tag pipeline.
Shares Cetrelimab, Johnson & Johnson and the tag pipeline.
Shares Abiraterone acetate, Prednisone, Prostate cancer and the tag pipeline.
Shares Niraparib, PARP inhibitors and the tag pipeline.